Company Overview and News

 
French and Benelux stocks-Factors to watch on March 2

2018-03-02 reuters
March 2 (Reuters) - Below are company-related news and stories from French and Benelux media which could have an impact on the region’s markets or individual stocks.
Upvote Downvote

 
Figeac Aero Supplying Aluminum Boeing 777X Parts

2018-01-11 aviationweek
LYON, France—Figeac Aero has won its first contract as a direct supplier with Boeing. It is for large structural aluminum parts on the 777X. The wing component is described as 4 m (13 ft.) long, 1 m wide and 0.15 m thick. The 3,300-employee company will define the manufacturing processes at its headquarters in Figeac, France. Production will take place at Figeac Aero’s Wichita, Kansas, factory because its surface treatment methods are approved by Boeing, a Figeac Aero .
Upvote Downvote

 
Spirit Aerosystems Awards Big Contract To Figeac Aero

2017-01-25 aviationweek
WICHITA—Figeac Aero has been awarded the largest contract in its company’s history by Wichita-based Spirit AeroSystems. Under the eight-year contract, Figeac Aero will build primary parts and subassemblies for Airbus A350 and Boeing 737, 747-8, 767 and 777 aircraft. Figeac Aero will provide Spirit with small-, medium- and large-size aluminum and titanium mechanical components and subassemblies. Figeac Aero did not release the value of the contract, which it calls .
Upvote Downvote

 
La plus grosse compétition d'entreprises d'Europe nomme les 12 meilleures entreprises

2016-06-18 prnewswire
Les entreprises lauréates du programme European Business Awards 2015/16 ont été couronnées lors d'une soirée de gala à Milan  
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...